Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report

Takafumi Suzuki1*, Kazutsugu Iwamoto2, Ryoichi Nozaki3, Yasumitsu Saiki1, Masafumi Tanaka1, Mitsuko Fukunaga1 and Kazutaka Yamada1

Abstract

Background: Gastrointestinal lymphomas like diffuse large B-cell lymphoma (DLBCL) are rare complications of ulcerative colitis (UC), and only a few studies have reported intestinal ulcers caused by DLBCL, which got perforated during the treatment of UC.

Case presentation: A 43-year-old man with severe lower abdominal pain and an 8-year history of UC was admitted in our hospital. He was diagnosed UC since 8 years and received a maintenance oral dose of 5-aminosalicylic acid, and no other immunsuppressive drugs. A deep rectal ulcer was endoscopically diagnosed 10 months before admission, no malignancy or cytomegalovirus infection was detected on biopsy. After 7 months a further endoscopy with biopsies confirmed the finding and the absence of malignancy. Three months later the patient developed sudden abdominal pain and was admitted in our hospital. Rectal perforation was suspected on X-ray and computed tomography imaging, and an emergency surgery was performed. Surgical exploration revealed a perforation on the anterior wall of the rectum. A subtotal colectomy with temporary ileostomy was performed. Pathology examinations showed lymphocyte infiltration of all of the layers of the perforated site and an immunohistochemical evaluation revealed DLBCL. Clinical staging was stage IV, and the patient received a 6-months regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy. Positron emission tomography restaging revealed disappearance of distant uptake and a slight uptake in the residual rectum, and completion proctectomy with ileal pouch-anal anastomosis was performed. No residual tumor in the specimen was found, and the patient was disease-free at 2 years follow-up.

Conclusions: DLBCL may increase the frequency of perforation and is a poor prognostic risk factor for patients with UC. This case study emphasizes the importance of careful medical surveillance and repeated endoscopic biopsies during the treatment of UC.

Keywords: Diffuse large B-cell lymphoma, Ulcerative colitis, Intestinal perforation
gastrointestinal lymphoma is relatively high [2–4]. Therefore, gastrointestinal lymphomas can increase the risk of perforation in patients with UC.

Colon cancer is a common complication of UC, but inflammatory bowel disease (IBD), on its own, is not recognized as a risk factor for gastrointestinal lymphoma [5–8]. Previous studies have shown that long-term immunosuppressive drugs and tumor necrosis factor (TNF) inhibitor therapy in patients with UC induce gastrointestinal lymphoma [9, 10]. It has been suggested that long-term therapy with immunosuppressive drugs and TNF inhibitor cause immunosuppression and increase the incidence of Epstein-Barr virus (EBV)—positive lymphomas (i.e., diffuse large B-cell lymphoma (DLBCL)) [11]. However, other studies have reported cases of DLBCL in UC patients not treated with immunosuppressive drugs and TNF inhibitors [12, 13].

Here, we report a case of rectal DLBCL that got perforated while the patient was being treated with 5-amino-salicylic acid (5-ASA) and prednisolone for UC.

**Case presentation**

A 43-year-old man with severe lower abdominal pain was admitted to our hospital for medical treatment. He had an 8-year history of ulcerative proctitis, a form of UC. When the diagnosis of UC was made, he was administered a maintenance oral dose of 5-ASA, and no other immunosuppressive drugs (i.e., azathioprine and TNF inhibitors) were prescribed. Ten months before the onset of the sudden abdominal pain, a deep rectal ulcer was detected on endoscopy. An endoscopic examination revealed a grade 3 ulcer according to the Mayo endoscopic subscore (Fig. 1). Inflammation of the mucosa near the ulcer was slight and diagnosed as grade 1. On biopsy performed at the same time, there was no malignancy or cytomegalovirus (CMV) infection. The posology of 5-ASA was increased; he began taking a daily suppository of 5-ASA and Budesonide. Three months before the onset of the sudden abdominal pain, another endoscopic biopsy from the ulcer and pathological analysis were performed. Similar to the last time, the ulcer was diagnosed as grade 3, and there was no malignancy. Five days prior to the onset of the sudden abdominal pain, a daily dose of 40 mg of oral prednisolone was prescribed for the ulcer, as we clinically diagnosed that it did not respond to 5-ASA and Budesonide. Laboratory investigations revealed a slightly elevated C-reactive protein level, an elevated white blood cell count, no increase in tumor markers (carcinoembryonic antigen = 0.16 mg/L and white blood cell count (7700/μL). Abdominal X-ray showed colon distension. Computed tomography (CT) of the abdomen and pelvis revealed intraperitoneal free air and an abnormal colon distension (Fig. 2a). The pelvic CT scan also suggested a perforation of the rectum but did not clearly reveal the presence of the lymphoma (Fig. 2b). These results indicated that the patient had a perforation rectal ulcer secondary to active UC. A subtotal colectomy with end ileostomy was performed. During the surgery, a fistula was discovered at the rectosigmoid region (Fig. 3). Pathological examination of the resected rectum revealed atypical lymphocyte infiltration in all of the layers of the rectal wall. Inflammation of the rectal mucosa in the non-perforated part was mild and evaluated as grades 1–2 according to Matt’s histological classification. There was no inflammation of the colonic mucosa (Fig. 4). Immunohistochemical staining was positive for the following: cluster of differentiation 20 (CD 20) markers, cluster of differentiation 10 (CD 10) markers, B-cell lymphoma 6 (BCL-6) proteins and multiple myeloma oncogene 1 (MUM-1)-stained atypical lymphocytes (Fig. 5). From these results, the pathological findings revealed that rectal perforation was related to DLBCL with UC. The stained specimen on immunohistochemistry was also positive for EBV (Fig. 6).

A postoperative fluorodeoxyglucose-positron emission tomography revealed an abnormal uptake in the postero-inferior area of the liver surface (S 7) and in the residual rectum margin. The standardized uptake value max (SUV max) of the liver region was 7.2, and the SUV max of the
residual rectum was 11.1. Consequently, the patient was evaluated as having stage IV lymphoma according to the Lugano classification [14] and was treated with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) 2 months after the surgery. Six courses of chemotherapy were effective in correcting the abnormal uptake in the liver region without any complications. However, the abnormal uptake in the residual rectal wall slightly persisted after the six courses (SUV max = 3.6). Ileal pouch-anal anastomosis was performed 9 months after the primary surgery, and a histopathological examination of the residual rectum was done. There was no evidence of residual tumor, especially in the remnant rectal margin. The diverted ileostomy was closed, and he was disease-free. No recurrence was noted upon re-evaluation two years after his first surgery.

**Discussion and conclusions**

The incidence of perforation in UC patients is rare because the inflammation in UC is usually limited to the submucosa. Patients usually take high doses of steroids or immunosuppressive drugs for the treatment in the active phase UC. CMV infection counteracts the use of immunosuppressive drugs and favors the development of toxic megacolon, which is a major cause of perforation in UC. The incidence rate of perforation in UC is reported to be around 3% [1].

However, the incidence rate of perforations in gastrointestinal lymphoma is approximately 9–22% and is higher than that in high-grade lymphoma (i.e., DLBCL) [2–4]. Primary gastrointestinal lymphoma may decrease the mechanical strength of the gastrointestinal wall and cause intestinal perforation [3, 15]. Some studies have found that perforation is a poor prognostic factor in
patients with high-grade lymphomas like DLBCL [2–4, 16]. Vaidya reported that nearly half of the perforation events in gastrointestinal lymphoma occur at the time of diagnosis of gastrointestinal lymphoma suggesting that these perforations could not be avoided by prior interventions [3]. Thus, it may be important to diagnose gastrointestinal lymphoma before it gets perforated, especially in UC patients.

The risk of gastrointestinal lymphoma is not higher in UC patients than in the general population [7]. Several previous studies have found that UC patients receiving thiopurines exhibit markedly increased relative risk of gastrointestinal lymphoma [9, 10]. Kandiel et al. reported an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine [9]. Moreover, more than 90% of UC patients with gastrointestinal lymphoma receiving thiopurines complained of EBV infections [11]. Immunosuppressive therapy induces EBV infection and EBV-positive lymphomas (i.e., DLBCL). However, some studies have reported

Fig. 5 Immunohistochemical examinations from the perforation site. Atypical lymphocytes are CD 20 positive (a), CD 10 positive (b), BCL-6 positive (c), and MUM-1 positive (d), (× 200)

Fig. 6 Tumor cells are positive for EBV on in situ hybridization, suggesting that tumor cells are infected with EBV (× 200)
cases where DLBCL occurred in UC patients who were not administered immunosuppressive drugs [12, 13]. These cases suggest that DLBCL may occur regardless of whether immunosuppressive drugs are used or not.

In this case study, abnormal colon distension due to progression of the UC led to perforation of the DLBCL-induced ulcer. Immunosuppressive drugs were not administered, while steroids were administered only 5 days prior to the perforation. The incidence rate of perforation in patients with UC is low. However, whether the prevalence of gastrointestinal lymphoma in UC patients is high or not is still unclear, but the incidence rate of perforations in gastrointestinal lymphoma is relatively high. DLBCL may increase the frequency of perforation and is a poor prognostic risk factor for patients with UC. In this case, we performed two pre-operative endoscopic biopsies of the ulcer, but we neither obtained a DLBCL-positive nor a CMV-infected specimen. DLBCL often causes ulcerations. Therefore, it is important to distinguish between a DLBCL ulcer and a UC ulcer by performing an endoscopic biopsy for choosing appropriate treatment for the ulcer. Hence, when a therapy-resistant colonic ulcer is detected in UC, biopsies from multiple points of the ulcer should be performed to confirm the presence of DLBCL to prevent perforation. In conclusion, gastrointestinal lymphomas such as DLBCL are rare in patients with UC, and bowel perforations induced by DLBCL ulcers in such patients are extremely rare. This case report emphasizes the importance of careful medical surveillance and repeated endoscopic biopsies in patients with UC.

Abbreviations
S-ASA: S-Aminosalicylic acid; CMV: Cytomegalovirus; DLBCL: Diffuse large B-cell lymphoma; EBV: Epstein–Barr virus; IB: Inflammatory bowel disease; MUM: Multiple myeloma oncogene; TNF: Tumor necrosis factor; UC: Ulcerative colitis.

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Authors’ contributions
ST conceptualized and wrote the original draft. SY, TM, FM, and YK treated the subject and revised the manuscript critically. IK and NR wrote, reviewed, and edited the work. All the authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Not applicable.

Ethical approval and consent to participate
The Institutional Review Board of Coloproctology Center Takano Hospital Ethics Committee approved to the present case report.

Consent for publication
Written informed consent for publication has been obtained from the patient. The consent can be provided on request.

Competing interests
The authors have no conflicts of interest to declare.

Author details
1 Department of Surgery, Coloproctology Center Takano Hospital, 3-2 Ooe, Kumamoto, Kumamoto 862-0971, Japan. 2 Department of Surgery, Shinkuku General Hospital, 418-1 Kamihayami, Kuki, Saitama 346-8530, Japan. 3 Department of Gastroenterology, Coloproctology Center Takano Hospital, 3-2 Ooe, Kumamoto, Kumamoto 862-0971, Japan.

Received: 8 October 2020 Accepted: 13 January 2021
Published online: 21 January 2021

References
1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.
2. Fuji T, Shiozawa E, Murakami M, Ono K, Kitajima T, Shibata H, et al. Clinicopathological examination of the surgical indication for a primary intestinal malignant lymphoma considering risk of intestinal complication. J Abdom Emerg Med. 2018;38:617–26.
3. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, et al. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013;24:4349–53.
4. Chuang SS, Ye H, Yang SF, Huang WT, Chen HK, Hsieh PP, et al. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma. Histopathology. 2008;53:432–40.
5. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:326–35.
6. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.
7. Allen PB, Laing G, Connolly A, O’Neill C. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem? BMJ Case Rep. 2013;2013:bcr201300423.
8. Herrinton LJ, Lu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–53.
9. Kandel A, Fraser AG, Korellitz B, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.
10. Ljung T, Karlén P, Schmidt D, Hellström PM, Lapduls A, Janeczewska I, et al. Inflimib in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–53.
11. Beigel F, Steinborn A, Schnitzler F, Tillack C, Breitenhecher S, John JM, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoeconomics Drug Saf. 2014;23(7):735–44.
12. Popp C, Stanicenu F, Micu G, Nichita L, Mateescu RM, Dimitriui L, et al. Long-standing ulcerative colitis complicated with mantle-cell lymphoma transformed in diffuse large B cell lymphoma. Rom J Intern Med. 2014;52:176–82.
13. Ashrafi F, Kowsari F, Darakshandeh A, Adibi P. Composite lymphoma in a patient with ulcerative colitis: a case report. Int J Hematol Oncol Stem Cell Res. 2014;4:845–8.
14. Rohatiner A, d’More F, Coffier B, Crowther D, Gospodarovschi M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.
15. Hiyama K, Terashima H, Nakano Y, Kamiga M, Harada K, Horiguchi H, et al. Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report. Clin Case Rep. 2015;2:150–5.
16. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–73.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.